Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects

European Journal of Clinical Pharmacology

Volumn 65, Issue 6, 2009, Pages 593-600

  Kodaira, Chise ^a   Sugimoto, Mitsushige ^a   Nishino, Masafumi ^a   Yamade, Mihoko ^a   Shirai, Naohito ^b   Uchida, Shinya ^c   Ikuma, Mutsuhiro ^a   Yamada, Shizuo ^c   Watanabe, Hiroshi ^a   Hishida, Akira ^a   Furuta, Takahisa ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Enshu General Hospital   (Japan)

^c UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

CYP2C19; Lansoprazole; MDR1; Polymorphism

Indexed keywords

2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ABCB1 PROTEIN, HUMAN; ANTIULCER AGENT; GLYCOPROTEIN P; LANSOPRAZOLE;

ADULT; ARTICLE; BIOAVAILABILITY; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HAPLOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JAPAN; MALE; STANDARD;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; JAPAN; MALE; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; REFERENCE STANDARDS;

EID: 68849100449     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-009-0625-8     Document Type: Article

References (36)

1. Nagaya H, Satoh H, Maki Y (1990) Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther 252 (3):1289-1295 (Pubitemid 20127442)
2. Nagaya H, Inatomi N, Nohara A et al (1991) Effects of the enantiomers of lansoprazole (AG-1749) on (H++K+)-ATPase activity in canine gastric microsomes and acid formation in isolated canine parietal cells. Biochem Pharmacol 42(10):1875-1878
3. Blum RA (1996) Lansoprazole and omeprazole in the treatment of acid peptic disorders. Am J Health Syst Pharm 53(12):1401-1415
4. Lockhart SP (1994) Clinical review of lansoprazole. Br J Clin Pract Suppl 75:48-55 discussion 56-57
5. Langtry HD, Wilde MI (1997) Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 54(3):473-500 (Pubitemid 27395597)
6. Inatomi N, Nagaya H, Takami K et al (1991) Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats. Jpn J Pharmacol 55(4):437-451
7. Carswell CI, Goa KL (2001) Rabeprazole: an update of its use in acid-related disorders. Drugs 61(15):2327-2356 (Pubitemid 34082706)
8. Unge P (1996) Review of Helicobacter pylori eradication regimens. Scand J Gastroenterol Suppl 215:74-81
9. Asaka M, Sugiyama T, Kato M et al (2001) A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 6(3):254 -261
10. Furuta T, Futami H, Arai H et al (1995) Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori. J Clin Gastroenterol 20(Suppl 2):S107-111
11. Furuta T, Shirai N, Sugimoto M et al (2004) Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 5(2):181-202 (Pubitemid 38351277)
12. Miura M, Tada H, Yasui-Furukori N et al (2004) Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. Eur J Clin Pharmacol 60(9):623-628 (Pubitemid 40064594)
13. Furuta T, Ohashi K, Kosuge K et al (1999) CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65(5):552-561 (Pubitemid 29237329)
14. Furuta T, Ohashi K, Kamata T et al (1998) Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 129 (12):1027-1030 (Pubitemid 29005826)
15. Murakami K, Sato R, Okimoto T et al (2002) Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 16(11):1933-1938 (Pubitemid 35253009)
16. Kullak-Ublick GA, BeckerMB(2003) Regulation of drug and bile salt transporters in liver and intestine. Drug Metab Rev 35(4):305-317 (Pubitemid 38018109)
17. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M et al (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398 (Pubitemid 29222564)
18. Hitzl M, Drescher S, van der Kuip H et al (2001) The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+natural killer cells. Pharmacogenetics 11(4):293-298 (Pubitemid 32537402)
19. Hoffmeyer S, Burk O, von Richter O et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with Pglycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97(7):3473-3478 (Pubitemid 30183327)
20. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF (2001) Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 364 (6):551-557 (Pubitemid 33145095)
21. Gawronska-Szklarz B, Wrzesniewska J, Starzynska T et al (2005) Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. Eur J Clin Pharmacol 61(5-6):375-379 (Pubitemid 41569312)
22. Furuta T, Sugimoto M, Shirai N et al (2007) Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. Aliment Pharmacol Ther 26(5):693-703 (Pubitemid 47246197)
23. Kim RB, Leake BF, Choo EF et al (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70(2):189-199 (Pubitemid 32777772)
24. Wasilewska A, Zalewski G, Chyczewski L et al (2007) MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children. Pediatr Nephrol 22(1):44 -51
25. Chowbay B, Li H, David M, Cheung YB et al (2005) Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 60(2):159-171 (Pubitemid 41075901)
26. Kubota T, Chiba K, Ishizaki T (1996) Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60(6):661 -666
27. Cascorbi I, Gerloff T, Johne A et al (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69(3):169-174 (Pubitemid 32225417)
28. Komoto C, Nakamura T, Sakaeda T et al (2006) MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet 21(2):126-132
29. Kawai T, Kawakami K, Kudo T, Ogiahara S et al (2002) A new serum antibody test kit (E plate) for evaluation of Helicobacter pylori eradication. Intern Med 41(10):780-783 (Pubitemid 35314775)
30. Sugimoto M, Furuta T, Shirai N et al (2004) Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 76(4):290-301 (Pubitemid 39313119)
31. Nakamura T, Sakaeda T, Horinouchi M et al (2002) Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71 (4):297-303 (Pubitemid 34311459)
32. Horinouchi M, Sakaeda T, Nakamura T et al (2002) Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res 19(10):1581-1585 (Pubitemid 35266567)
33. Tang K, Ngoi SM, Gwee PC et al (2002) Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12(6):437 -450
34. Park HJ, Shinn HK, Ryu SH et al (2007) Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clin Pharmacol Ther 81(4):539-546 (Pubitemid 46452300)
35. Kim KA, Park PW, Park JY (2007) Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. Br J Clin Pharmacol 63 (1):53-58
36. Miura M, Satoh S, Tada H et al (2006) Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensivemetabolizers and treated with tacrolimus. Int J Clin Pharmacol Ther 44(12):605-613 (Pubitemid 44896138)